Key result
An increase in NT-proBNP during the first year of follow-up independently predicted mortality in wild-type transthyretin amyloid cardiomyopathy (HR 1.07 per 500 ng/L increase; 95% CI 1.02-1.13; p=0.007).
Why the study?
Clinical course varies substantially between individuals with wtATTR-CM, and there are currently no established measures of rate of disease progression.
Does change in NT-proBNP at 1 year predict mortality in patients with wild-type transthyretin amyloid cardiomyopathy?
Population
432 patients with wtATTR-CM diagnosed at the UK NAC receiving no disease-modifying therapy
Comparison
Change in functional, biochemical, and echocardiographic variables from diagnosis to 12 months
Design
Retrospective observational study
Authors
Loading...
ΔNT-proBNP rise may aid mortality risk stratification in wtATTR-CM; leaves open whether serial monitoring alters management or outcomes.
Observational (n=432)
No
Does change in NT-proBNP at 1 year predict mortality in patients with wild-type transthyretin amyloid cardiomyopathy?
Hazard Ratio: 1.07 (95% CI 1.02–1.13)
p-value: p=0.007
An increase in NT-proBNP during the first year of follow-up is a powerful independent predictor of mortality in patients with wild-type transthyretin amyloid cardiomyopathy.
Law et al. (2021) conducted an observational in Wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM) (n=432). Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration was evaluated on Mortality from the 12-month timepoint (HR 1.07 per 500 ng/L increase, 95% CI 1.02 to 1.13, p=0.007). An increase in NT-proBNP during the first year of follow-up independently predicted mortality in wild-type transthyretin amyloid cardiomyopathy (HR 1.07 per 500 ng/L increase; 95% CI 1.02-1.13; p=0.007).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: